FIDUCIARY TRUST CO - GLOBAL BLOOD THERAPEUTICS IN ownership

GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 189 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.18 and the average weighting 0.1%.

Quarter-by-quarter ownership
FIDUCIARY TRUST CO ownership history of GLOBAL BLOOD THERAPEUTICS IN
ValueSharesWeighting
Q2 2022$369,000
-7.8%
11,5500.0%0.01%
+14.3%
Q1 2022$400,000
+18.3%
11,5500.0%0.01%
+16.7%
Q4 2021$338,000
+15.0%
11,5500.0%0.01%
+20.0%
Q3 2021$294,000
-27.2%
11,5500.0%0.01%
-37.5%
Q2 2021$404,000
-14.2%
11,5500.0%0.01%
-20.0%
Q1 2021$471,000
-5.8%
11,5500.0%0.01%0.0%
Q4 2020$500,000
-21.5%
11,5500.0%0.01%
-33.3%
Q3 2020$637,000
-12.6%
11,5500.0%0.02%
-16.7%
Q2 2020$729,000
+23.6%
11,5500.0%0.02%
+5.9%
Q1 2020$590,000
-35.7%
11,550
-0.0%
0.02%
-19.0%
Q4 2019$918,000
+63.6%
11,5530.0%0.02%
+50.0%
Q3 2019$561,000
-7.7%
11,553
+0.0%
0.01%
-12.5%
Q2 2019$608,000
-0.5%
11,5500.0%0.02%0.0%
Q1 2019$611,000
-31.0%
11,550
-46.4%
0.02%
-40.7%
Q4 2018$885,000
+8.1%
21,5500.0%0.03%
+17.4%
Q3 2018$819,000
-15.9%
21,5500.0%0.02%
-20.7%
Q2 2018$974,000
-6.4%
21,5500.0%0.03%
-9.4%
Q1 2018$1,041,000
-4.1%
21,550
-21.9%
0.03%0.0%
Q4 2017$1,086,000
+48.4%
27,604
+17.1%
0.03%
+39.1%
Q3 2017$732,000
+22.4%
23,580
+7.8%
0.02%
+27.8%
Q2 2017$598,000
+16.6%
21,879
+57.3%
0.02%
+12.5%
Q1 2017$513,00013,9090.02%
Other shareholders
GLOBAL BLOOD THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Alerce Investment Management, L.P. 356,270$24,262,00023.36%
Twin Securities, Inc. 376,669$25,651,00011.94%
Paradigm Biocapital Advisors LP 1,175,879$80,077,00010.68%
Chicago Capital Management, LLC 246,246$16,769,0009.12%
HARVEST MANAGEMENT LLC 141,500$9,636,0007.78%
Fernwood Investment Management, LLC 174,724$11,899,0005.02%
ArchPoint Investors 168,725$11,490,0004.69%
HAVENS ADVISORS LLC 46,000$3,133,0004.69%
Perceptive Advisors 2,322,247$158,145,0004.59%
Crabel Capital Management, LLC 112,680$7,674,0004.48%
View complete list of GLOBAL BLOOD THERAPEUTICS IN shareholders